Frequently Asked Questions

Your study treatment could be the study drug, Xaluritamig, or an existing treatment option for mCRPC. There is no placebo in this study. Everyone receives a cancer drug.

The allocation process will be done by a computer and you may be assigned, by chance, to 1 of 2 groups, like flipping a coin. This process is known as randomization.

No. There is no placebo in this study.

You will be in the study for about 5 years. How long you take the study treatment depends on how your cancer responds to it and how your body handles any possible side effects.

As with any cancer drug, there is a risk of side effects. The study doctor will explain the possible side effects to you and tell you what to watch out for. The study doctor will watch over your health and well-being closely to identify any problems. Tell your study doctor about anything that is bothering you so that together, you can make appropriate decisions about your cancer care.

There will be frequent visits with the study doctor, who may be the same doctor you already see for your cancer care. Your condition may get better, but it could stay the same or even get worse. What is learned from this study may help future patients like you.

This study does not replace your regular medical care. If you need medical care during the study, contact your regular doctor and let the study staff know.

Study-related treatment, tests, and doctor visits will be provided at no cost to you. You will continue to pay for costs that are not related to the study, which may include medical care for your cancer or other conditions.

You will not be paid to be in the study. You may be paid back for reasonable out-of-pocket costs such as travel to the study clinic. Ask the study staff what kind of financial support you can expect.

Having a representative study population helps to address gaps in medical knowledge and inequality in healthcare for men with prostate cancer. When the men in the study represent the real-world patient population, the results are more trustworthy.

The study is sponsored by Amgen, an American-based biotechnology company that strives to serve patients by transforming the promise of science and biotechnology into therapies that have the power to restore health or save lives.

If you are interested in learning more or possibly joining the study, ask your Oncologist about the XALute Study.